Chromatin Biology and 3D Genome Organisation

Introduction to Chromatin Biology

In eukaryotic cells, the ~2 metres of genomic DNA must be compacted into a nucleus just 5-10 micrometres in diameter—a compaction ratio of approximately 400,000-fold. This packaging is achieved through chromatin: DNA wrapped around histone octamers forming nucleosomes, nucleosomes folded into higher-order structures, and ultimately chromosomal loops and domains organised within the nucleus. Chromatin is not merely a packaging solution but an active regulatory system: nucleosome positioning, histone modifications, chromatin remodelling complexes, and three-dimensional organisation collectively control which genes are accessible and expressed in each cell type and each context.

The epigenetic complexity of chromatin represents a second layer of genomic information—the same DNA sequence packaged differently produces the >200 distinct cell types comprising the human body. Disruptions of chromatin regulators cause developmental disorders, intellectual disability, and cancer. Understanding chromatin biology is essential for interpreting how regulatory variants (non-coding GWAS variants often affect enhancer accessibility) cause genomic disease, how cancer epigenomes are altered, and how epigenetic reprogramming during development and reprogramming to iPSCs resets chromatin states.

Chromatin Structure

Nucleosome Biology

Nucleosomes consist of 147 bp DNA wrapped 1.65 times around a histone octamer (two copies each of H2A, H2B, H3, H4). The histone octamer has a structured core and flexible N-terminal tails extending from the surface. Post-translational modifications of histone tails—acetylation, methylation, phosphorylation, ubiquitination—are added by writer enzymes, removed by erasers, and recognised by reader domains that recruit effector complexes. Active promoters carry H3K4me3; active enhancers H3K4me1 and H3K27ac; active transcription H3K36me3; heterochromatin H3K9me3; Polycomb-silenced regions H3K27me3. These histone marks collectively constitute the histone code.

Chromatin Remodelling

ATP-dependent chromatin remodelling complexes use nucleosome sliding, histone eviction, or histone variant exchange to alter chromatin accessibility. SWI/SNF (BAF/PBAF) complexes slide and eject nucleosomes to open chromatin at regulatory elements. ISWI complexes space nucleosomes evenly for regular chromatin compaction. CHD complexes perform varied functions including repression and nucleosome assembly. NuRD complex couples histone deacetylase activity with chromatin remodelling for transcriptional repression. Mutations in SWI/SNF subunits (ARID1A, SMARCA4, SMARCB1) occur in 20% of all human cancers—making the SWI/SNF complex the most commonly mutated chromatin regulator in human malignancy.

Histone Modifications and Regulatory Elements

Enhancers and Promoters

Enhancers are distal regulatory DNA sequences (kbp to Mbp from their target genes) that drive cell-type-specific gene expression by binding combinations of transcription factors. Active enhancers are marked by H3K4me1 and H3K27ac, are accessible to ATAC-seq and DNase-seq, and are transcribed to produce enhancer RNAs (eRNAs). Super-enhancers—unusually large (>10 kb) clusters of active enhancers—drive transcription of cell identity and oncogene (MYC, BCL2) genes with exceptional strength. Enhancer hijacking by chromosomal rearrangements placing proto-oncogenes near super-enhancers drives cancer—seen in medulloblastoma (GATA3, OTX2), ALL (IGH-MYC), and others.

Polycomb and Trithorax

Polycomb repressive complexes (PRC1 and PRC2) maintain stable epigenetic silencing of developmental genes—including HOX clusters—in inappropriate cell lineages. PRC2 writes H3K27me3 (EZH2 catalytic subunit); H3K27me3 is recognised by PRC1 canonical Polycomb-domain proteins. Trithorax group complexes (MLL/COMPASS) counteract Polycomb, depositing H3K4me3 at active developmental loci. NSD1/2 histone methyltransferases deposit H3K36me2 marking actively transcribed gene bodies. Bivalent chromatin—concurrent H3K4me3 and H3K27me3 at regulatory genes—is characteristic of ESCs and progenitors, enabling rapid activation upon differentiation signals. MLL gene translocations in infant ALL create fusion oncoproteins with aberrant gene activation activity.

3D Genome Organisation

Hi-C (genome-wide chromosome conformation capture) revealed that genomes are organised into hierarchical 3D structures: A/B compartments (active/inactive chromatin segregating in the nucleus), topologically associating domains (TADs—self-interacting chromosomal regions 40 kb-3 Mb insulated by CTCF and cohesin), and chromatin loops. Enhancer-promoter loops bring regulatory elements into proximity with their target genes across genomic distances; loss of TAD insulation (through CTCF site mutation or deletion) causes enhancer-promoter rewiring in cancer and developmental disease. Phase separation—condensate formation by intrinsically disordered regions of transcription factors and coactivators—may underlie transcriptional hub formation at super-enhancers.

Examples and Applications

Example 1: ATAC-Seq Chromatin Accessibility

ATAC-seq (Assay for Transposase-Accessible Chromatin using sequencing) uses hyperactive Tn5 transposase to insert sequencing adapters preferentially into nucleosome-depleted (accessible) chromatin regions—identifying all active regulatory elements genome-wide in 500 cells. Single-cell ATAC-seq (scATAC-seq) maps regulatory elements in individual cells, enabling identification of cell type-specific regulatory programs in complex tissues and tracing regulatory changes during differentiation. Integration with scRNA-seq pairs chromatin accessibility with gene expression cell-by-cell. Regulatory variant interpretation uses ATAC-seq to identify whether a GWAS variant falls in accessible chromatin in relevant cell types, prioritising functionally active variants for functional follow-up.

Example 2: EZH2 Inhibition in Cancer

EZH2 gain-of-function mutations (Y646N/F/H, A682G, A692V) occur in 20% of follicular lymphoma and 7% of DLBCL. These mutations increase EZH2 catalytic activity, causing H3K27me3 hypermethylation silencing genes opposing lymphoma development. Tazemetostat (EZH2 inhibitor) is FDA-approved for EZH2-mutant follicular lymphoma (showing 69% overall response rate) and epithelioid sarcoma (SMARCB1-deficient tumours requiring EZH2 for survival). EZH2 inhibition achieves differentiation of leukaemic cells in MLL-rearranged leukaemia models. SWI/SNF-deficient tumours (lacking SMARCB1, SMARCA4) develop dependency on EZH2 for survival—a classic synthetic lethality exploitable therapeutically.

Example 3: TAD Disruption in Limb Malformations

Lupianski et al. 2015 demonstrated that deletions/inversions at the EPHA4 locus in humans disrupted TAD boundaries, causing enhancer-promoter rewiring—normally PAX3-activating limb enhancers gained proximity to WNT6, IHH, or EPHA4 genes, causing ectopic expression and distinct limb malformations (polydactyly, brachydactyly) depending on which promoter was hijacked. These findings established that TAD boundaries are functionally critical for preventing enhancer-promoter cross-talk, and that structural variants disrupting boundaries cause diseases through regulatory rather than coding sequence alterations—an important mechanism for interpreting complex genomic structural variants.

Example 4: Bromodomain Inhibitors (BET Inhibitors)

BET proteins (BRD2, BRD3, BRD4) contain tandem bromodomains reading H3K27ac at active enhancers, recruiting P-TEFb to stimulate RNA Pol II elongation and driving transcription of oncogenes (MYC, BCL-2, IRF4) at super-enhancers in cancer cells. BRD4 inhibitors (JQ1, I-BET762, OTX015) disproportionately suppress transcription at super-enhancers compared to normal enhancers. In MYC-driven cancers (Burkitt lymphoma, NMC, myeloma), BET inhibition causes dramatic MYC suppression and cell death. Clinical trials in haematological malignancies and NMC (nuclear protein in testis carcinoma) showed antitumour activity; combination strategies are being pursued to overcome resistance mechanisms including MYC amplification.

Example 5: H3K27M Oncohistone in DIPG

Diffuse intrinsic pontine glioma (DIPG)—an incurable childhood brain tumour—carries K27M mutations in genes encoding histone H3 variants (H3F3A or HIST1H3B) in over 80% of cases. The K27M oncohistone acts as a dominant-negative inhibitor of PRC2, causing global H3K27me3 loss and activating normally silenced developmental genes. This epigenetic catastrophe drives glioma formation through altered neural progenitor cell differentiation. ONC201 (a DRD2/DRD3 antagonist) showed unexpectedly specific activity in H3K27M-mutant DIPG in clinical trials—FDA breakthrough designation granted. Understanding H3K27M mechanism led to development of ONC201 combinations now in registration-track trials.

Example 6: CTCF and Cohesin in Loop Extrusion

Hi-C and imaging studies established that chromatin loops are formed by loop extrusion: cohesin SMC ring complexes translocate along chromatin loading and unloading DNA until blocked by convergent CTCF sites, forming stable anchor loops. CTCF motifs define TAD boundaries; the 19-zinc-finger CTCF protein binds 55,000+ genomic sites. Cohesin depletion (acute auxin-inducible degron experiments) immediately abolished TAD boundaries and most enhancer-promoter loops. Cohesin and CTCF mutations in cancer alter loop architecture enabling oncogene activation. Understanding loop extrusion mechanics provides a biophysical framework for gene regulation and explains how linear DNA sequence instructions are implemented as 3D regulatory topology.

Example 7: DNA Methylation and Imprinting

Genomic imprinting—parent-of-origin-specific monoallelic expression—is maintained by differentially methylated regions (DMRs) established in gametes and maintained through somatic development. H19/IGF2 imprinted locus: maternal allele has methylated ICR blocking CTCF binding, allowing enhancers to activate IGF2; paternal allele has unmethylated ICR where CTCF binding insulates IGF2 from enhancers, activating H19 lncRNA instead. Beckwith-Wiedemann syndrome arises from loss of maternal imprinting allowing biallelic IGF2 expression. Angelman syndrome (UBE3A maternal loss) and Prader-Willi syndrome (paternal 15q deletion) illustrate that imprinting is essential for normal development and neurodevelopment.

Example 8: Pioneer Transcription Factors

Pioneer transcription factors (e.g., FoxA, GATA, Oct4) can bind closed heterochromatic DNA and open chromatin, initiating gene activation during differentiation and reprogramming. FoxA1 acts as a pioneer factor in liver development binding compacted hepatic gene promoters, recruiting chromatin remodelling complexes to open chromatin enabling subsequent transcription factor binding and gene activation. In cancer, FoxA1 is a pioneer factor for androgen receptor binding in prostate cancer—FoxA1 mutations in prostate cancer alter binding specificity enabling AR-independent oncogenic transcription. Understanding pioneer factor biology explains cell fate transitions and reveals cancer-specific transcriptional reprogramming mechanisms creating therapeutic vulnerabilities.

Try it live

Everything above runs in your browser — open Chromatin & 3D Genome Organisation and change the parameters while it is running. Nothing is installed, nothing is uploaded, the whole model lives in one tab.